Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Milan Lukas

Showing results (11-20 of 77) with videos related to

Pageof 8
Sort By:
Clinical Chemistry|May 30, 2008
Improved HPLC analysis of serum 7alpha-hydroxycholest-4-en-3-one, a marker of bile acid malabsorptionMartin Lenicek, Miroslava Juklova, Jaroslav Zelenka, et al.
Therapeutic Drug Monitoring|February 17, 2007
Monitoring of thiopurine methyltransferase activity in postsurgical patients with Crohn's disease during 1 year of treatment with azathioprine or mesalazineKarin Dilger, Elke Schaeffeler, Milan Lukas, et al.
Journal of Crohn'S & Colitis|April 2, 2011
The clinical implication of drug dependency in children and adults with inflammatory bowel disease: a reviewDana Duricova, Natalia Pedersen, Martin Lenicek, et al.
Journal of Crohn'S & Colitis|December 4, 2012
Infliximab trough levels may predict sustained response to infliximab in patients with Crohn's diseaseMartin Bortlik, Dana Duricova, Karin Malickova, et al.
World Journal of Gastroenterology|June 29, 2006
Deficiency of Adenomatous Polyposis Coli protein in sporadic colorectal adenomas and its associations with clinical phenotype and histologyMartin Bortlik, Ivana Vitkova, Martina Papezova, et al.
Expert Review of Gastroenterology & Hepatology|December 20, 2022
Patient-reported symptoms are a more reliable predictor of the societal burden compared to established physician-reported activity indices in inflammatory bowel disease: a cross-sectional studyBarbora Decker, Jan Tuzil, Milan Lukas, et al.
Inflammatory Bowel Diseases|June 16, 2011
Two independent genetic factors responsible for the associations of the IBD5 locus with Crohn's disease in the Czech populationOndrej Hradsky, Petra Dusatkova, Martin Lenicek, et al.
Digestive Diseases (Basel, Switzerland)|February 2, 2017
Infliximab Biosimilar (Remsima™) in Therapy of Inflammatory Bowel Diseases Patients: Experience from One Tertiary Inflammatory Bowel Diseases CentreM Kolar, D Duricova, M Bortlik, et al.
BMC Medical Genetics|June 12, 2010
The CTLA4 variants may interact with the IL23R- and NOD2-conferred risk in development of Crohn's diseaseOndrej Hradsky, Petra Dusatkova, Martin Lenicek, et al.
Journal of Crohn'S & Colitis|January 7, 2020
Switching From Originator Adalimumab to the Biosimilar SB5 in Patients With Inflammatory Bowel Disease: Short-term Experience From a Single Tertiary Clinical CentreMartin Lukas, K Malickova, M Kolar, et al.
Pageof 8

Showing results (11-20 of 77) with videos related to

Sort By:
Pageof 8
Clinical Chemistry|May 30, 2008
Improved HPLC analysis of serum 7alpha-hydroxycholest-4-en-3-one, a marker of bile acid malabsorptionMartin Lenicek, Miroslava Juklova, Jaroslav Zelenka, et al.
Therapeutic Drug Monitoring|February 17, 2007
Monitoring of thiopurine methyltransferase activity in postsurgical patients with Crohn's disease during 1 year of treatment with azathioprine or mesalazineKarin Dilger, Elke Schaeffeler, Milan Lukas, et al.
Journal of Crohn'S & Colitis|April 2, 2011
The clinical implication of drug dependency in children and adults with inflammatory bowel disease: a reviewDana Duricova, Natalia Pedersen, Martin Lenicek, et al.
Journal of Crohn'S & Colitis|December 4, 2012
Infliximab trough levels may predict sustained response to infliximab in patients with Crohn's diseaseMartin Bortlik, Dana Duricova, Karin Malickova, et al.
World Journal of Gastroenterology|June 29, 2006
Deficiency of Adenomatous Polyposis Coli protein in sporadic colorectal adenomas and its associations with clinical phenotype and histologyMartin Bortlik, Ivana Vitkova, Martina Papezova, et al.
Expert Review of Gastroenterology & Hepatology|December 20, 2022
Patient-reported symptoms are a more reliable predictor of the societal burden compared to established physician-reported activity indices in inflammatory bowel disease: a cross-sectional studyBarbora Decker, Jan Tuzil, Milan Lukas, et al.
Inflammatory Bowel Diseases|June 16, 2011
Two independent genetic factors responsible for the associations of the IBD5 locus with Crohn's disease in the Czech populationOndrej Hradsky, Petra Dusatkova, Martin Lenicek, et al.
Digestive Diseases (Basel, Switzerland)|February 2, 2017
Infliximab Biosimilar (Remsima™) in Therapy of Inflammatory Bowel Diseases Patients: Experience from One Tertiary Inflammatory Bowel Diseases CentreM Kolar, D Duricova, M Bortlik, et al.
BMC Medical Genetics|June 12, 2010
The CTLA4 variants may interact with the IL23R- and NOD2-conferred risk in development of Crohn's diseaseOndrej Hradsky, Petra Dusatkova, Martin Lenicek, et al.
Journal of Crohn'S & Colitis|January 7, 2020
Switching From Originator Adalimumab to the Biosimilar SB5 in Patients With Inflammatory Bowel Disease: Short-term Experience From a Single Tertiary Clinical CentreMartin Lukas, K Malickova, M Kolar, et al.
Pageof 8